Schizophrenia Clinical Trials in Los Angeles
View 161 new treatments for Schizophrenia in Los Angeles, CA, and nearby areas, such as Burbank, Downey, El Monte, Fullerton, Garden Grove, Glendale, Huntington Beach, Inglewood, Long Beach, Norwalk, Pasadena, Pasadena, Pomona, Santa Clarita, Torrance, Ventura and West Covina. Every day, Power helps hundreds of schiz patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
RL-007 for Cognitive Impairment in Schizophrenia
Recognify Life Sciences Clinic, Torrance + 10 more
This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.Show More
Verified
Recruiting
Phase 2
Est. 4 - 6 Weeks
Gary Walker, PhD
Study Director
Oxytocin for Schizophrenia
Research Clinic, Los Angeles + 1 more
This study will measure whether the engagement of intranasal oxytocin with a brain target is related to effects on learning during a social cognition training program.Show More
Waitlist
Phase 4
Est. 6 - 12 Weeks
Stephen Marder, MD
Principal Investigator
Clozapine for Schizophrenia
Research Clinic, Los Angeles + 1 more
This trial is testing whether clozapine can reduce violent behavior more effectively than usual treatments in adults with schizophrenia who have recently been violent. Clozapine helps by balancing brain chemicals to manage symptoms. The study will last for several months and include regular medical check-ups. Clozapine has been shown to reduce violent and aggressive behavior in patients with schizophrenia, especially those who are treatment-resistant.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Ragy Girgis, MD
Principal Investigator
KarXT for Schizophrenia
Karuna Clinic, Riverside + 9 more
This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Ronald Marcus, MD
Study Director
Lumateperone for Schizophrenia and Bipolar Disorder
Intra-Cellular Therapies Clinic, Long Beach + 2 more
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia or bipolar disorder.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Cariprazine for Adolescent Schizophrenia
Allergan Clinic, Culver City + 1 more
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Recruiting
Phase 3
Est. 5 - 8 Weeks
Paul Yeung
Study Director
Long-term Safety of Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Culver City + 13 more
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Brilaroxazine for Schizophrenia
Reviva Clinic, Garden Grove + 1 more
This trial tests Brilaroxazine, a daily pill, in patients with severe mental health issues. It aims to improve mood and reduce symptoms. The study lasts for more than a year.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Medical Director
Study Director
SEP-363856 for Schizophrenia
Sunovion Clinic, Anaheim + 4 more
This trial is testing a new schizophrenia medication called SEP-363856 in people who have already started using it. The goal is to see if it is safe and effective over several months. The medication works by affecting brain chemicals to help reduce symptoms of schizophrenia.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
CNS Medical Director
Study Chair
KarXT for Schizophrenia
Karuna Clinic, Los Alamitos + 3 more
The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Bristol-Myers Squibb
Study Director
Page 1 of 4
Frequently Asked Questions
Explore related conditions